Diamicron

Diamicron

A brand name for GLICLAZIDE.
References in periodicals archive ?
Tenders are invited for Gliclazide Xr 60 Mg Metformin Hcl Xr 500Mg Tab Brand- Diamicron Xr Mex 500
But 5-year follow-up results of patients originally enrolled in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial (N.
However, because of results from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, simply focusing on intensive glycemic control in post-MI patients with newly diagnosed diabetes is probably not an ideal management approach, he acknowledged.
Although epidemiological connections remain under debate (1,4-6), recent large randomized trials [Action to Control Cardiovascular Disease in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE), and VA Diabetes Trial (VADT)] have failed to translate tight control of [Hb A.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) (108), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) (109), and Veterans Affairs Diabetes Trial (VADT) (110) studies randomized 10251, 11140, and 1791 T2DM patients, respectively, with co-existing risk factors and/or history of diabetic complications (including previous CVD events) into intensive (aiming for bold "near-normal" glycaemic targets) or conventional therapy groups, using different treatment regimens.
ADVANCE Action in Diabetes and Vascular disease: PreterAx and DiamicroN MR Controlled Evaluation) was designed, conducted, monitored, analyzed, and reported by a collaborative medical research group supported by the Australian Government's National Health and Medical Research Council after full peer review.
Q I had diet-controlled diabetes which has just progressed to required Diamicron tablets.
It has been marketed as Glyloc and Reclide in India and Diamicron in Canada.
Similar results were observed in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial.
MONTREAL, October 20 /PRNewswire/ -- New results from ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, provide important insights into the therapeutic strategy to adopt for efficient and safe blood glucose control aimed at the reduction of severe diabetes complications.
The finding of no benefit of intensive glycemic control on CVD risk is concordant with results of 2 other trials conducted with somewhat similar cohorts, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial and the Veterans Affairs Diabetes Trial (VADT).
The choice of Diamicron MR was based on its well known efficacy and safety profile, as proven by millions of diabetic patients treated every day.